Surgical Oncology Principles Practice Questions

Q: Which of the following is NOT included in the TNM staging system?

Tumour site. The **TNM Staging System**, developed by the AJCC (American Joint Committee on Cancer) and the UICC, is the global standard for classifying the extent of malignant disease. It is based on the anatomical extent of the tumor rather than its specific location within an organ. ### **Explanation of the Correct Answer** **B. Tumour site:** While the site of the tumor determines which specific TNM manual/criteria to apply (e.g., breast vs. colon), the **site itself is not a component** of the staging formula. The TNM system focuses on the *progression* of the disease (size, spread to nodes, and distant spread) rather than the anatomical coordinate. ### **Why the Other Options are Incorrect** * **A. Tumour size (T):** Describes the size and local extent of the primary tumor. In many cancers (like breast or lung), the "T" stage is determined by the maximum diameter in centimeters. * **C. Nodal involvement (N):** Describes the presence, number, or location of regional lymph node metastases. This is a critical prognostic factor in surgical oncology. * **D. Metastasis (M):** Indicates the presence (M1) or absence (M0) of distant spread to other organs or non-regional lymph nodes. ### **High-Yield Clinical Pearls for NEET-PG** * **Clinical vs. Pathological Staging:** **cTNM** is based on physical exam and imaging before treatment; **pTNM** is based on histopathological examination after surgery. * **The "Ann Arbor" Exception:** Remember that the TNM system is used for **solid tumors**. Lymphomas are staged using the **Ann Arbor classification**, and pediatric tumors often use site-specific systems (e.g., Wilms tumor uses NWTS staging). * **The "G" Factor:** While not part of the "TNM" acronym, **Histological Grade (G)** is often used alongside TNM to determine the overall Stage Grouping (I-IV). * **Sentinel Lymph Node Biopsy (SLNB):** This is the standard procedure to determine the 'N' status in clinically node-negative breast cancer and melanoma.

Q: Which of the following is often biopsied to assess the presence of metastatic lesion in lymph nodes?

Sentinel lymph node. ### Explanation **1. Why Option D is Correct:** The **Sentinel Lymph Node (SLN)** is defined as the **first lymph node** (or group of nodes) that receives lymphatic drainage directly from a primary tumor. The underlying oncological principle is that if a cancer spreads via the lymphatic system, the sentinel node will be the first site of metastasis. * **Clinical Significance:** If the SLN is negative for malignancy upon biopsy (using techniques like Technetium-99 sulfur colloid or Methylene blue dye), it is highly probable that the remaining nodes in that basin are also clear. This allows surgeons to avoid morbid procedures like Radical Axillary or Inguinal Lymph Node Dissections. **2. Why Other Options are Incorrect:** * **Option A:** The "last lymph node" would be the final filter before lymph enters the venous system (e.g., the thoracic duct). Biopsying this would not help in early staging or determining the initial spread. * **Option B & C:** Size is an unreliable indicator of metastasis. A **large node** may simply be reactive (inflammatory), while a **small node** can harbor microscopic metastatic deposits (micrometastasis). The "Sentinel" status is determined by **drainage patterns**, not physical dimensions. **3. High-Yield Clinical Pearls for NEET-PG:** * **Most Common Indications:** Breast Cancer (T1/T2) and Malignant Melanoma. * **Technique:** The "Combined Method" (Radio-isotope + Blue dye) has the highest identification rate (>95%). * **Contraindications:** Inflammatory breast cancer, clinically palpable/positive nodes (N1/N2), and large tumors (>5cm). * **Skip Metastasis:** A phenomenon where the SLN is negative but higher nodes are positive; though rare, it is a known limitation of SLNB.

Q: Which type of thyroid tumor is considered extremely lethal?

Anaplastic carcinoma. **Explanation:** **Anaplastic Thyroid Carcinoma (ATC)** is the correct answer because it is one of the most aggressive and lethal solid tumors in humans. It represents only 1–2% of thyroid cancers but accounts for the majority of thyroid cancer-related deaths. The underlying medical concept is its **undifferentiated nature**; the cells lose all functional and structural characteristics of normal thyroid tissue, leading to rapid local invasion of the neck (trachea, esophagus, and vessels) and early distant metastasis. The 5-year survival rate is dismal, often less than 5%, with most patients succumbing within 6 months of diagnosis. **Why other options are incorrect:** * **Papillary Carcinoma (B):** This is the most common thyroid cancer and has an excellent prognosis (95% 10-year survival). It spreads via lymphatics but is slow-growing. * **Follicular Carcinoma (D):** This is the second most common type. While more aggressive than papillary due to hematogenous spread, it still carries a favorable prognosis when localized. * **Medullary Carcinoma (A):** Arising from parafollicular C-cells, it has an intermediate prognosis. While more aggressive than differentiated cancers (Papillary/Follicular), it is significantly less lethal than the anaplastic variety. **High-Yield Clinical Pearls for NEET-PG:** * **Demographics:** ATC typically presents in the 6th–7th decade of life, often arising from a pre-existing long-standing goiter or differentiated thyroid cancer. * **Clinical Presentation:** Rapidly enlarging neck mass causing "pressure symptoms" like dyspnea, dysphagia, and hoarseness (RLN involvement). * **Histology:** Characterized by spindle, giant, or squamoid cells with high mitotic figures. * **Management:** Often unresectable at presentation; treatment is primarily palliative (radiotherapy/chemotherapy) or tracheostomy to secure the airway.

Q: Bone metastasis is common in which type of thyroid tumor?

Hürthle cell tumor. **Explanation:** The correct answer is **Hürthle cell tumor**. While follicular carcinoma is traditionally known for hematogenous spread, Hürthle cell carcinoma (a variant of follicular carcinoma) is significantly more aggressive. It has a higher propensity for distant metastasis, particularly to the **bones** and lungs, compared to other differentiated thyroid cancers. Approximately 35% of patients with Hürthle cell carcinoma present with or develop distant metastases. **Analysis of Options:** * **A. Follicular Carcinoma:** This tumor characteristically spreads via the bloodstream (hematogenous). While it frequently involves the bone, Hürthle cell tumors are considered more aggressive with a higher rate of distant failure. * **B. Papillary Carcinoma:** This is the most common thyroid cancer. Its primary mode of spread is **lymphatic** to the cervical lymph nodes. Distant bone metastasis is rare (usually <5-10%). * **D. Anaplastic Carcinoma:** This is a highly aggressive, undifferentiated tumor. While it spreads rapidly and widely, it usually causes death through local invasion and airway obstruction before bone metastases become the defining clinical feature. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Spread:** Papillary = Lymphatic; Follicular/Hürthle = Hematogenous. * **Hürthle Cell Characteristics:** These cells are rich in **mitochondria** (oxyphilic). Unlike follicular cancer, Hürthle cell tumors are often **not** iodine-avid, making radioactive iodine (RAI) therapy less effective. * **Most Common Site of Bone Metastasis:** The spine is the most frequent site for thyroid cancer deposits. * **Orphan Annie Eyes:** Pathognomonic for Papillary Thyroid Carcinoma.

Q: What is the most common site for bone metastasis in carcinoma of the breast in women?

Spine. **Explanation:** **1. Why the Spine is Correct:** In breast carcinoma, bone is the most common site of distant metastasis. The **spine (specifically the thoracic and lumbar regions)** is the most frequent site of skeletal involvement. This predilection is primarily explained by the **Batson’s venous plexus**—a valveless system of vertebral veins that communicates directly with the intercostal veins. During episodes of increased intra-abdominal or intra-thoracic pressure, cancer cells can bypass the systemic circulation (and the lungs) to seed directly into the vertebral column. **2. Analysis of Incorrect Options:** * **Skull (A):** While breast cancer can metastasize to the skull, it occurs significantly less frequently than in the axial skeleton. * **Ribs (B):** Ribs are common sites for metastasis due to their proximity to the primary tumor, but they rank lower in frequency compared to the vertebral column. * **Pelvis (D):** The pelvis is the second most common site for bone metastasis in breast cancer after the spine. **3. Clinical Pearls for NEET-PG:** * **Nature of Lesion:** Breast cancer bone metastases are typically **osteolytic** (most common), though they can be osteoblastic or mixed. * **Diagnostic Gold Standard:** **MRI** is the most sensitive modality for detecting early marrow involvement. However, a **Technetium-99m Bone Scan** is the standard screening tool for identifying "hot spots" (increased osteoblastic activity). * **Management:** Bisphosphonates (like Zoledronic acid) or Denosumab are used to reduce skeletal-related events (SREs) such as pathological fractures and cord compression. * **Order of Frequency:** Spine > Pelvis > Femur > Ribs > Skull.

Q: A tumor invades the muscularis propria and involves 2 lymph nodes. According to the TNM staging system, what is the stage?

T2 N1. ### Explanation The TNM staging system is the global standard for classifying the extent of cancer, where **T** describes the primary tumor size/depth, **N** describes regional lymph node involvement, and **M** describes distant metastasis. **1. Why T2 N1 is Correct:** * **T (Tumor):** In most gastrointestinal and hollow organ staging (like the stomach or colon), **T2** is defined as a tumor that invades the **muscularis propria**. * *T1* involves the lamina propria or submucosa. * *T3* extends through the muscularis propria into the subserosa or non-peritonealized tissues. * **N (Nodes):** **N1** typically denotes involvement of **1 to 3 regional lymph nodes**. Since the question specifies 2 nodes, it fits the N1 category. **2. Why the Other Options are Incorrect:** * **T2 N2:** While T2 is correct for muscularis propria invasion, **N2** usually signifies involvement of **4 or more** regional lymph nodes (depending on the specific organ site). * **T3 N1:** T3 is incorrect because the tumor has only reached the muscularis propria; it has not yet penetrated through it into the subserosa. * **T3 N2:** This is incorrect on both counts: the T-stage is over-staged (should be T2) and the N-stage is over-staged (should be N1). **High-Yield Clinical Pearls for NEET-PG:** * **T4** usually indicates invasion into adjacent organs or perforation of the visceral peritoneum. * **Tis** stands for *Carcinoma in situ* (confined to the epithelium, no basement membrane invasion). * **Prognostic Significance:** In many cancers, the **N-status** (nodal involvement) is the most significant prognostic factor for overall survival. * **Sentinel Lymph Node Biopsy (SLNB):** This is the standard of care for staging the axilla in breast cancer and the regional nodes in melanoma when no nodes are clinically palpable.

Q: What is the preferred single-agent chemotherapy drug for carcinoma of the cheek?

Cisplatin. **Explanation:** **Cisplatin** is the gold-standard single-agent chemotherapy drug for Squamous Cell Carcinoma (SCC) of the head and neck, including carcinoma of the cheek (buccal mucosa). Its mechanism involves forming intra-strand cross-links in DNA, which inhibits replication and triggers apoptosis. In clinical practice, Cisplatin is preferred because it acts as a potent **radiosensitizer**, making it the drug of choice for concurrent chemoradiotherapy (CRT) to improve local control and survival rates. **Analysis of Incorrect Options:** * **Vincristine (Option A):** A vinca alkaloid that inhibits microtubule formation. While used in pediatric solid tumors and lymphomas, it has minimal efficacy in head and neck epithelial cancers. * **Cyclophosphamide (Option B):** An alkylating agent primarily used in breast cancer, lymphomas, and leukemias. It is not a primary agent for oral cavity SCC. * **Daunorubicin (Option D):** An anthracycline used almost exclusively in hematological malignancies like Acute Myeloid Leukemia (AML). It has no role in the management of cheek carcinoma. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** Cisplatin is the most effective single agent for head and neck SCC. * **Side Effects:** The dose-limiting toxicity of Cisplatin is **Nephrotoxicity** (prevented by aggressive pre- and post-treatment hydration/amifostine). It is also highly emetogenic and can cause ototoxicity. * **Alternative:** If a patient has renal impairment, **Carboplatin** is the preferred substitute. * **Targeted Therapy:** **Cetuximab** (an EGFR inhibitor) is another high-yield drug used in advanced head and neck cancers.

Q: Chemotherapy is useful in all the following conditions, except?

Carcinoma cervix. **Explanation:** The core principle behind this question lies in distinguishing between **chemosensitive** tumors (where chemotherapy is a primary or curative modality) and tumors where chemotherapy plays a secondary, palliative, or adjuvant role. **Why Carcinoma Cervix is the correct answer:** In the context of this question, **Carcinoma Cervix** is primarily managed via **Surgery** (for early stages, e.g., Wertheim’s Hysterectomy) or **Radiotherapy/Chemoradiotherapy** (for advanced stages). While cisplatin is used as a radiosensitizer, chemotherapy alone is rarely "useful" as a primary curative modality compared to the other options listed. It is generally reserved for recurrent or metastatic disease. **Analysis of Incorrect Options:** * **Ewing’s Sarcoma:** This is a highly chemosensitive tumor. Neoadjuvant chemotherapy (VAC/IE regimen) is the standard of care to shrink the tumor and treat micrometastases before local control (surgery/radiation). * **Germ Cell Tumors (GCTs):** These are the hallmark of successful chemotherapy. Even in metastatic stages, platinum-based regimens (BEP) offer high cure rates, making chemotherapy a definitive treatment. * **Secondaries (Metastasis):** For many systemic cancers (like lymphoma, small cell lung cancer, or certain breast cancers), chemotherapy is the mainstay of treatment for "secondaries" to achieve systemic control and prolong survival. **High-Yield Clinical Pearls for NEET-PG:** * **Highly Chemosensitive Tumors:** Choriocarcinoma, Germ cell tumors, Ewing’s sarcoma, Wilms’ tumor, and Lymphomas. * **Radiosensitive Tumors:** Seminoma, Dysgerminoma, and Basal Cell Carcinoma. * **Carcinoma Cervix Standard:** The "Gold Standard" for Stage IIB to IVA is **Concurrent Chemoradiotherapy (CCRT)**, where cisplatin is used to enhance the effect of radiation, not as a standalone curative agent.

Q: Which of the following statements about soft tissue sarcoma is true?

TNM staging is performed for soft tissue sarcomas.. ### Explanation **1. Why Option D is Correct:** Soft tissue sarcomas (STS) are staged using the **AJCC/UICC TNM system**. Unlike many other cancers, the staging of STS is unique because it heavily incorporates **Histological Grade (G)** alongside Tumor size (T), Node involvement (N), and Metastasis (M). Grade is the most important prognostic factor for STS. **2. Why the Other Options are Incorrect:** * **Option A:** Liposarcoma is actually one of the **most common** soft tissue sarcomas in adults (along with Undifferentiated Pleomorphic Sarcoma). It is frequently found in the retroperitoneum and extremities. * **Option B:** For lesions **greater than 5 cm**, the gold standard is a **Core Needle Biopsy (CNB)**, not an incisional biopsy. Incisional biopsy is reserved for cases where CNB is non-diagnostic. If performed, the incision must be longitudinal and placed such that the entire scar can be excised during definitive surgery. * **Option C:** FNAC is generally **not diagnostic** for STS. While it can confirm malignancy or recurrence, it cannot provide adequate tissue architecture to determine the specific histological subtype or grade, which is essential for treatment planning. **3. High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Lower extremity (specifically the thigh). * **Mode of spread:** Primarily **hematogenous** (most common site of metastasis is the **Lung**). * **Lymphatic spread:** Rare, but seen in "SCARE" (Synovial, Clear cell, Angiosarcoma, Rhabdomyosarcoma, Epithelioid sarcoma). * **Pseudocapsule:** Sarcomas are surrounded by a zone of compressed neoplastic and inflammatory cells; simple "shelling out" leads to high recurrence. * **Treatment:** Wide local excision with radiotherapy is the standard for most high-grade or large tumors.

Question 1

Which of the following is NOT included in the TNM staging system?

Accepted Answer

Tumour site

Answer

Tumour size

Answer

Nodal involvement

Answer

Metastasis

Question 2

Which of the following is often biopsied to assess the presence of metastatic lesion in lymph nodes?

Accepted Answer

Sentinel lymph node

Answer

Last lymph node that receives lymph flow from the primary tumor

Answer

Smallest lymph node in the region of the primary tumor

Answer

Largest lymph node in the region of the primary tumor

Question 3

Which type of thyroid tumor is considered extremely lethal?

Accepted Answer

Anaplastic carcinoma

Answer

Medullary carcinoma

Answer

Papillary carcinoma

Answer

Follicular carcinoma

Question 4

Bone metastasis is common in which type of thyroid tumor?

Accepted Answer

Hürthle cell tumor

Answer

Follicular

Answer

Papillary

Answer

Anaplastic

Question 5

What is the most common site for bone metastasis in carcinoma of the breast in women?

Accepted Answer

Spine

Answer

Skull

Answer

Ribs

Answer

Pelvis

Question 6

A tumor invades the muscularis propria and involves 2 lymph nodes. According to the TNM staging system, what is the stage?

Accepted Answer

T2 N1

Answer

T2 N2

Answer

T3 N1

Answer

T3 N2

Question 7

What is the preferred single-agent chemotherapy drug for carcinoma of the cheek?

Accepted Answer

Cisplatin

Answer

Vincristine

Answer

Cyclophosphamide

Answer

Daunorubicin

Question 8

Chemotherapy is useful in all the following conditions, except?

Accepted Answer

Carcinoma cervix

Answer

Ewing's sarcoma

Answer

Germ cell tumor

Answer

Secondaries

Question 9

In which of the following conditions is neo-adjuvant chemotherapy NOT used?

Accepted Answer

Breast cancer stage 2

Answer

Osteosarcoma

Answer

PNET of the chest wall

Answer

Ovarian cancer stage 3

Question 10

Which of the following statements about soft tissue sarcoma is true?

Accepted Answer

TNM staging is performed for soft tissue sarcomas.

Answer

Liposarcoma is rare.

Answer

Incisional biopsy is indicated for lesions greater than 5 cm.

Answer

Fine needle aspiration cytology (FNAC) is diagnostic.

Surgical Oncology Principles — MCQs

Surgical Oncology Principles — MCQs

On this page

Practice by Chapter

Want unlimited practice?